• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 6

Aurobindo Pharma Ltd (APL) has announced that the US Food and Drug Administration (US FDA) has approved its Ciprofloxacin tablets in strengths 250, 500 and 750mg. Ciprofloxacin is the generic international name for the synthetic microbicide manufactured and sold by Bayer Pharmaceutical under the brand names Cipro, Ciproxin and Ciprobay.

Ciprofloxacin is considered a yardstick with which the other quinolones efficacies are measured against. Ciprofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, according to a release from the Hyderabad-based pharma major. The product is used in lower respiratory infections (pneumonias), urinary tract infections, STDs, septicemias, Legionellosis and in some atypicals. APL has also said that the company regrets its earlier announcement of cefpodoxime proxetil approval, which was displayed by the FDA on their Web site. However, this product is still awaiting official approval.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Great Eastern Energy reports growth in CBM reserves

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line